| By order of the Board: Ben Harber Company Secretary March | | | Registered Office: One Central Square Cardiff, CF10 1FS, U.K. | |
| | | Page | | |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 15 | | | |
| | | | | | ||
| | | | 16 | | | |
| | | | 18 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| |
| | | Page | | |||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 44 | | | |
| | | | 44 | | | |
| | | | 44 | | | |
| | | | | |
Proposal | | | Description of Proposal | | | Board’s Recommendation | |
1 | | | To re-elect | | | FOR | |
2 | | | To re-elect | | | FOR | |
3 | | | To re-elect | | | FOR | |
4 | | | To re-elect | | | FOR | |
5 | | | To | | | FOR | |
6 | | | To receive and adopt the 2023 U.K. Annual Report | | | FOR | |
7 | | | To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report | | | FOR | |
| | To receive and approve the U.K. Directors’ Remuneration Policy | | | FOR | | |
9 | | | To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration to £750,000 | | | FOR | |
10 | | | To re-appoint | | | FOR | |
| | To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, | | | FOR | | |
| | To approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers | | | FOR | | |
13 | | | To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of | | | FOR | |
| | To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if Section 561(1) of the Companies Act does not apply to any such allotment | | | FOR | |
| | | The Board of Directors unanimously recommends a vote FOR the re-election of Lisa Deschamps as a Director of the Company | |
| | | The Board of Directors unanimously recommends a vote FOR the re-election of Martin Edwards, M.D. as a Director of the Company | |
| | | The Board of Directors unanimously recommends a vote FOR the re-election of | |
| | | The Board of Directors unanimously recommends a vote FOR the re-election of | |
| | | The Board of Directors unanimously recommends a vote FOR the re-election of | |
Name | | Age | | Director Since | | Position(s) | | | Age | | Director Since | | Position(s) | | ||||||
David Zaccardelli, Pharm.D. | | 57 | | 2020 | | Chief Executive Officer and Director | | | 59 | | 2020 | | Chief Executive Officer and Director | | ||||||
David Ebsworth, Ph.D. | | 67 | | 2014 | | Non-Executive Chairperson of the Board of Directors | | | 69 | | 2014 | | Non-Executive Chairperson of the Board of Directors | | ||||||
Christina Ackermann | | 59 | | 2023 | | Non-Executive Director | | |||||||||||||
Michael Austwick | | 54 | | 2024 | | Non-Executive Director | | |||||||||||||
James Brady | | 59 | | 2022 | | Non-Executive Director | | | 61 | | 2022 | | Non-Executive Director | | ||||||
Martin Edwards, M.D. | | 66 | | 2019 | | Non-Executive Director | | |||||||||||||
Ken Cunningham, M.D. | | 69 | | 2015 | | Non-Executive Director | | | 71 | | 2015 | | Non-Executive Director | | ||||||
Lisa Deschamps | | 50 | | 2021 | | Non-Executive Director | | | 52 | | 2021 | | Non-Executive Director | | ||||||
Rishi Gupta | | 44 | | 2016 | | Non-Executive Director | | |||||||||||||
Martin Edwards, M.D. | | 68 | | 2019 | | Non-Executive Director | | |||||||||||||
Mahendra Shah, Ph.D. | | 77 | | 2016 | | Non-Executive Director | | | 79 | | 2016 | | Non-Executive Director | | ||||||
Andrew Sinclair, Ph.D.* | | 50 | | 2016 | | Non-Executive Director | | |||||||||||||
Vikas Sinha | | 58 | | 2016 | | Non-Executive Director | | | 60 | | 2016 | | Non-Executive Director | | ||||||
Anders Ullman, M.D., Ph.D. | | 66 | | 2015 | | Non-Executive Director | | | 68 | | 2015 | | Non-Executive Director | |
| Board Diversity Matrix (As of March | | |||
| Country of Principal Executive Offices | | | United Kingdom | |
| Foreign Private Issuer | | | No | |
| Disclosure Prohibited Under Home Country Law | | | No | |
| Total Number of Directors | | | 11 | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 1 | | | | | | 10 | | | | | | — | | | | | | — | | |
Part II: Demographic Background | | | | | |||||||||||||||||||||
Underrepresented Individual in Home Country Jurisdiction | | | | | | | | | | | | | | | | | 4 | | | | | | | | |
LGBTQ+ | | | | | | | | | | | | | | | | | 1 | | | | | | | | |
Did Not Disclose Demographic Background | | | | | | | | | | | | | | | | | — | | | | | | | | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 2 | | | | | | 9 | | | | | | — | | | | | | — | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
Underrepresented Individual in Home Country Jurisdiction | | | | | | | | | | | | | | | | | 6 | | | | | | | | |
LGBTQ+ | | | | | | | | | | | | | | | | | 1 | | | | | | | | |
Did Not Disclose Demographic Background | | | | | | | | | | | | | | | | | — | | | | | | | | |
| | | The Board of Directors unanimously recommends a vote FOR the receipt and adoption of the | |
| | | The Board of Directors unanimously recommends a vote FOR the receipt and approval, as a non-binding advisory resolution, of the U.K. statutory Directors’ Remuneration Report | |
| | | The Board of Directors unanimously recommends a vote FOR the | |
| | | The Board of Directors unanimously recommends a vote FOR the increase in the maximum aggregate level of Non-Executive Director annual remuneration of £750,000 per annum | |
| | | The Board of Directors unanimously recommends a vote FOR the appointment of EY as the Company’s auditor | |
Fee Category | | | 2021 | | | 2020 | | ||||||
Audit Fees | | | | $ | 453,000 | | | | | $ | 318,000 | | |
Audit-Related Fees | | | | $ | 162,000 | | | | | $ | 348,000 | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | $ | 231,000 | | | | | $ | 198,000 | | |
Total Fees | | | | $ | 846,000 | | | | | $ | 864,000 | | |
Fee Category | | | 2023 | | | 2022 | | ||||||
Audit Fees | | | | $ | 900,000 | | | | | $ | 420,000 | | |
Audit-Related Fees | | | | $ | 158,000 | | | | | $ | 201,000 | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | $ | 97,000 | | | | | $ | 403,000 | | |
Total Fees | | | | $ | 1,155,000 | | | | | $ | 1,024,000 | | |
| | | The Board of Directors unanimously recommends a vote FOR authorization of the Audit Committee to determine EY’s remuneration for the year ending December 31, 2024 | |
| | | The Board of Directors unanimously recommends a vote FOR | |
| | | The Board of Directors unanimously recommends a vote FOR the authorization of Directors to exercise all the powers to the Company to allot shares in the Company or grant Rights up to an aggregate nominal amount of | |
| | | The Board of Directors unanimously recommends a vote FOR the authorization of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if Section 561(1) of the Companies Act does not apply to any such allotment | |
Name | | | Age | | | Position | |
David Zaccardelli, Pharm.D.(1) | | | | | President, Chief Executive Officer and Executive Director | | |
| | | | | |||
| | | | | |||
Kathleen Rickard, M.D.(4) | | | | | Chief Medical Officer | |
Name | | | Audit and Risk | | | Remuneration | | | Nomination and Corporate Governance | |
Christina Ackermann | | | X | | | | | | | |
Ken Cunningham, M.D. | | | | | | Chair | | | | |
James Brady | | | X | | | | | | | |
Lisa Deschamps | | | | | | | | | X | |
David Ebsworth, Ph.D. | | | X | | | X | | | Chair | |
Mahendra Shah, Ph.D. | | | | | | X | ||||
| | | | |||||||
Vikas Sinha | | | Chair | | | | | | |
Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(1) | | | Non-Equity Incentive Plan Compensation ($) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||||||||||||||
David Zaccardelli | | | | | 2021 | | | | | | 272,500 | | | | | | — | | | | | | 496,035 | | | | | | — | | | | | | 328,313 | | | | | | 26,456(2) | | | | | | 1,123,304 | | |
President and Chief Executive Officer | | | | | 2020 | | | | | | 229,167 | | | | | | — | | | | | | 17,620,462 | | | | | | — | | | | | | 412,500 | | | | | | 39,110 | | | | | | 18,301,239 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | | | |
Mark Hahn | | | | | 2021 | | | | | | 402,500 | | | | | | — | | | | | | 99,210 | | | | | | — | | | | | | 218,875 | | | | | | 17,704(3) | | | | | | 738,289 | | |
Chief Financial Officer | | | | | 2020 | | | | | | 229,167 | | | | | | — | | | | | | 17,915,584 | | | | | | — | | | | | | 275,000 | | | | | | 35,047 | | | | | | 18,454,798 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | | | |
Kathleen Rickard | | | | | 2021 | | | | | | 413,751 | | | | | | — | | | | | | — | | | | | | — | | | | | | 140,675 | | | | | | 7,957(4) | | | | | | 562,383 | | |
Chief Medical Officer | | | | | 2020 | | | | | | 401,700 | | | | | | 125,000 | | | | | | 3,201,340 | | | | | | 42,013 | | | | | | 176,748 | | | | | | 19,314 | | | | | | 3,966,115 | | |
Name and Principal Position | | | Year | | | Cash Base Salary ($) | | | Stock Awards ($)(1) | | | Non-Equity Incentive Plan Compensation ($) | | | All Other Compensation ($) | | | Total ($) | | ||||||||||||||||||
David Zaccardelli, Pharm.D. | | | | | 2023 | | | | | | 819,568 | | | | | | 5,324,000 | | | | | | 440,705 | | | | | | 13,200(2) | | | | | | 6,597,473 | | |
President and Chief Executive Officer (PEO) | | | | | 2022 | | | | | | 524,842 | | | | | | 4,133,500 | | | | | | 497,297 | | | | | | 27,501 | | | | | | 5,183,140 | | |
Mark W. Hahn | | | | | 2023 | | | | | | 551,291 | | | | | | 5,324,000 | | | | | | 293,803 | | | | | | 13,200(2) | | | | | | 6,182,294 | | |
Chief Financial Officer | | | | | 2022 | | | | | | 430,450 | | | | | | 3,983,498 | | | | | | 331,531 | | | | | | 22,401 | | | | | | 4,767,880 | | |
Kathleen Rickard, M.D. | | | | | 2023 | | | | | | 458,333 | | | | | | 1,331,000 | | | | | | 192,500 | | | | | | — | | | | | | 1,981,833 | | |
Chief Medical Officer | | | | | 2022 | | | | | | 434,439 | | | | | | 863,000 | | | | | | 217,220 | | | | | | 3,342 | | | | | | 1,518,001 | | |
Name | | 2021 Cash Annual Base Salary ($) | | 2022 Cash Annual Base Salary ($) | | | 2023 Annual Base Salary ($) | | 2024 Annual Base Salary ($) | | ||||||||||||||||
David Zaccardelli(1) | | | | 272,500 | | | | | 524,842 | | | | | | 839,437 | | | | | 873,015 | | | ||||
Mark Hahn(1) | | | | 402,500 | | | | | 430,450 | | | |||||||||||||||
Mark W. Hahn(1) | | | | 559,625 | | | | | 582,010 | | | |||||||||||||||
Kathleen Rickard | | | | 413,751 | | | | | 434,439 | | | | | | 458,333 | | | | | 504,167 | | |
| | | | | | | Option Awards | | Stock Awards | | | | | | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Grant Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | | Grant Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David Zaccardelli | | | | 5/7/2020(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 296,230 | | | | | 1,990,666 | | | | | — | | | | | — | | | | | | | 5/7/2020(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 32,914 | | | | | 654,330 | | | | | — | | | | | — | | | ||||||||||||||||||
| | | | 8/20/2020(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 1,004,177 | | | | | 6,748,069 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 1/28/2021(2) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 16,534 | | | | | 111,108 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark Hahn | | | | 5/7/2020(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 222,173 | | | | | 1,493,003 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 8/20/2020(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 1,078,234 | | | | | 7,245,732 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 1/28/2021(2) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 3,307 | | | | | 22,223 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
David Zaccardelli | | | | | 8/20/2020(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 111,577 | | | | | 2,218,151 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 9/26/2022(2) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 337,500 | | | | | 6,709,500 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10/20/2023(3) | | | | | | | | | | | | | | | | | | | | | | | | | 100,000 | | | | | 1,988,000 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10/20/2023(4) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | | | | | | | | | 300,000 | | | | | 5,964,000 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 5/7/2020(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 24,685 | | | | | 490,738 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark W. Hahn | | | | | 8/20/2020(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 119,802 | | | | | 2,381,664 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 9/26/2022(2) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 337,500 | | | | | 6,709,500 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10/20/2023(3) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 100,000 | | | | | 1,988,000 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10/20/2023(4) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 300,000 | | | | | 5,964,000 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4/1/2019 | | | | | 40,833 | | | | | 29,167(3) | | | | | — | | | | | 5.99 | | | | | 3/29/2029 | | | | | — | | | | | — | | | | | 15,000(4) | | | | | 100,800 | | | | | | 4/1/2019 | | | | | 70,000 | | | | | — | | | | | 5.99 | | | | | 3/29/2029 | | | | | — | | | | | — | | | | | | | | | | | | | ||||||||||||||||||||
| | | | 3/3/2020(5) | | | | | 5,469 | | | | | 7,031 | | | | | — | | | | | 5.64 | | | | | 3/3/2030 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 8/20/2020(6) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 263,583 | | | | | 1,771,278 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kathleen Rickard | | | | | 3/3/2020 | | | | | 11719 | | | | | 781(5) | | | | | 5.64 | | | | | 3/3/2030 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 8/20/2020(6) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 71,887 | | | | | 1,429,114 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 9/26/2022(2) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 75,000 | | | | | 1,491,000 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10/20/2023(3) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 25,000 | | | | | 497,000 | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 10/20/2023(4) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 75,000 | | | | | 1,491,000.00 | | |
Year | | | Summary Compensation Table Total for PEO ($) | | | Compensation Actually Paid to PEO ($)(1) | | | Average Summary Compensation Table Total for Non-PEO NEOs ($) | | | Average Compensation Actually Paid to Non-PEO NEOs ($)(1) | | | Value of Initial Fixed $100 Investment Based on: | | | Net Income ($) | | ||||||||||||||||||
| Total Shareholder Return ($) | | |||||||||||||||||||||||||||||||||||
2023 | | | | | 6,559,277 | | | | | | 558,317 | | | | | | 4,082,064 | | | | | | 207,291 | | | | | | 284.00 | | | | | | (54,369,000) | | |
2022 | | | | | 5,183,140 | | | | | | 27,578,945 | | | | | | 3,142,941 | | | | | | 17,462,808 | | | | | | 373.29 | | | | | | (68,701,000) | | |
2021 | | | | | 1,123,304 | | | | | | 823,718 | | | | | | 650,336 | | | | | | 425,254 | | | | | | 96.00 | | | | | | (55,569,000) | | |
Year | | | PEO | | | Non-PEO NEOs | |
2023 | | | David Zaccardelli | | | Mark W. Hahn and Kathleen Rickard | |
2022 | | | David Zaccardelli | | | Mark W. Hahn and Kathleen Rickard | |
2021 | | | David Zaccardelli | | | Mark W. Hahn and Kathleen Rickard | |
| | | 2023 | | |||||||||
Adjustments | | | PEO | | | Average Non-PEO NEOs | | ||||||
Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY | | | | | (5,324,000) | | | | | | (3,327,500) | | |
Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | | | | | 7,952,000 | | | | | | 4,970,000 | | |
Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date | | | | | — | | | | | | — | | |
Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | | | | | (3,012,444) | | | | | | (2,185,934) | | |
| | | 2023 | | |||||||||
Adjustments | | | PEO | | | Average Non-PEO NEOs | | ||||||
Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | | | | | (5,616,516) | | | | | | (3,331,338) | | |
Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End | | | | | — | | | | | | — | | |
Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date | | | | | — | | | | | | — | | |
Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY | | | | | — | | | | | | — | | |
TOTAL ADJUSTMENTS | | | | | (6,000,960) | | | | | | (3,874,772) | | |
Name | | | Fees Earned or Paid in Cash ($)(1) | | | Stock Awards ($)(1) | | | Option Awards ($)(2) | | | Total ($) | | ||||||||||||
Ken Cunningham | | | | | 54,143 | | | | | | — | | | | | | 33,757 | | | | | | 87,900 | | |
Lisa Deschamps | | | | | 37,224 | | | | | | 134,705 | | | | | | 33,757 | | | | | | 205,686 | | |
Rishi Gupta | | | | | 46,022 | | | | | | — | | | | | | 33,757 | | | | | | 79,779 | | |
Mahendra Shah | | | | | 44,668 | | | | | | — | | | | | | 33,757 | | | | | | 78,425 | | |
Andrew Sinclair | | | | | 47,375 | | | | | | — | | | | | | 33,757 | | | | | | 81,132 | | |
Vikas Sinha | | | | | 56,850 | | | | | | — | | | | | | 33,757 | | | | | | 90,607 | | |
Anders Ullman | | | | | 40,607 | | | | | | — | | | | | | 33,757 | | | | | | 74,364 | | |
Martin Edwards | | | | | 40,607 | | | | | | — | | | | | | 33,757 | | | | | | 74,364 | | |
David Ebsworth | | | | | 158,369 | | | | | | — | | | | | | 33,757 | | | | | | 192,126 | | |
Name | | | Fees Earned or Paid in Cash ($)(1) | | | Option Awards ($)(2) | | | Total ($) | | |||||||||
David Ebsworth | | | | | 148,962 | | | | | | 181,540 | | | | | | 330,502 | | |
Christina Ackermann | | | | | 14,106 | | | | | | 253,807 | | | | | | 267,913 | | |
James Brady | | | | | 44,561 | | | | | | 181,540 | | | | | | 226,101 | | |
Kenneth Cunningham | | | | | 50,927 | | | | | | 181,540 | | | | | | 232,467 | | |
Lisa Deschamps | | | | | 42,015 | | | | | | 181,540 | | | | | | 223,555 | | |
Martin Edwards | | | | | 38,195 | | | | | | 181,540 | | | | | | 219,735 | | |
Rishi Gupta | | | | | 38,195 | | | | | | 181,540 | | | | | | 219,735 | | |
Mahendra Shah | | | | | 43,288 | | | | | | 181,540 | | | | | | 224,828 | | |
Vikas Sinha | | | | | 57,293 | | | | | | 181,540 | | | | | | 238,833 | | |
Sven Ullman | | | | | 38,195 | | | | | | 181,540 | | | | | | 219,735 | | |
Name | | | Option Awards Outstanding at 2021 Fiscal Year End | | | Unvested Stock Awards Outstanding at 2021 Fiscal Year End | | ||||||
Ken Cunningham | | | | | 8,000 | | | | | | — | | |
Lisa Deschamps | | | | | 8,000 | | | | | | 3,625 | | |
Rishi Gupta | | | | | 31,200 | | | | | | — | | |
Mahendra Shah | | | | | 8,000 | | | | | | — | | |
Andrew Sinclair | | | | | 31,200 | | | | | | — | | |
Vikas Sinha | | | | | 23,048 | | | | | | — | | |
Anders Ullman | | | | | 8,000 | | | | | | — | | |
Martin Edwards | | | | | 8,000 | | | | | | — | | |
David Ebsworth | | | | | 8,000 | | | | | | — | | |
Name | | | Option Awards Outstanding at 2023 Fiscal Year End | | | Unvested Stock Awards Outstanding at 2023 Fiscal Year End | | ||||||
David Ebsworth | | | | | 39,000 | | | | | | 6,000 | | |
Christina Ackermann | | | | | — | | | | | | 18,000 | | |
James Brady | | | | | 42,000 | | | | | | 6,000 | | |
Ken Cunningham | | | | | 39,000 | | | | | | 6,000 | | |
Lisa Deschamps | | | | | 39,000 | | | | | | 6,000 | | |
Martin Edwards | | | | | 39,000 | | | | | | 6,000 | | |
Rishi Gupta | | | | | 62,200 | | | | | | 6,000 | | |
Mahendra Shah | | | | | 39,000 | | | | | | 6,000 | | |
Vikas Sinha | | | | | 54,048 | | | | | | 6,000 | | |
Anders Ullman | | | | | 39,000 | | | | | | 6,000 | | |
Plan Category | | Number of Ordinary Shares to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (a) | | Weighted- Average Exercise Price of Outstanding Options, Warrants and Rights (b) | | Number of Ordinary Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) (c) | | | Number of Ordinary Shares to be Issued Upon Exercise of Outstanding Options, Warrant and Rights (a) | | Weighted- Average Exercise Price of Outstanding Options, Warrant and Rights (b) | | Number of Ordinary Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) (c) | | ||||||||||||||||||||||||
Equity compensation plans approved by shareholders | | | | 51,042,552(1) | | | | $ | 1.53(2) | | | | | 22,387,225(3) | | | | | | 54,922,392(1) | | | | $ | 1.56(2) | | | | | 2,899,715(3) | | | ||||||
Equity compensation plans not approved by shareholders | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | ||||||
Total | | | | 51,042,552 | | | | $ | 1.53 | | | | | 22,387,225 | | | | | | 54,922,392 | | | | $ | 1.56 | | | | | 2,899,715 | | |
| | | Shares beneficially owned | | |||||||||
Name of beneficial owner | | | Number | | | Percent | | ||||||
5% or greater shareholders: | | | | | | | | | | | | | |
RA Capital Management affiliates(1) | | | | | 48,246,144 | | | | | | 9.99% | | |
AI Biotechnology LLC(2) | | | | | 44,444,448 | | | | | | 9.2% | | |
New Enterprise Associates affiliates(3) | | | | | 42,638,131 | | | | | | 8.8% | | |
OrbiMed affiliates(4) | | | | | 42,093,330 | | | | | | 8.7% | | |
Wellington Management affiliates(5) | | | | | 38,655,904 | | | | | | 8.0% | | |
Named Executive Officers, Directors and Director Nominees: | | | | | | | | | | | | | |
David Zaccardelli, Pharm.D.(6) | | | | | 7,257,304 | | | | | | 1.5% | | |
Ken Cunningham, M.D.(7) | | | | | 114,584 | | | | | | * | | |
Lisa Deschamps(8) | | | | | 118,320 | | | | | | * | | |
David Ebsworth, Ph.D.(9) | | | | | 737,560 | | | | | | * | | |
Martin Edwards, M.D.(10) | | | | | 126,776 | | | | | | * | | |
Rishi Gupta(11) | | | | | 233,600 | | | | | | * | | |
Mahendra Shah, Ph.D.(12) | | | | | 121,080 | | | | | | * | | |
Andrew Sinclair, Ph.D.(13) | | | | | 233,600 | | | | | | * | | |
Vikas Sinha(14) | | | | | 242,824 | | | | | | * | | |
Anders Ullman, M.D., Ph.D.(15) | | | | | 382,856 | | | | | | * | | |
James Brady | | | | | — | | | | | | * | | |
Mark W. Hahn(16) | | | | | 6,445,048 | | | | | | 1.3% | | |
Kathleen Rickard, M.D. (17) | | | | | 1,411,960 | | | | | | * | | |
All directors and executive officers as a group (14 persons)(18) | | | | | 19,506,146 | | | | | | 3.9% | | |
| | | Shares beneficially owned | | |||||||||
Name of beneficial owner | | | Number | | | Percent | | ||||||
5% or greater shareholders: | | | | | | | | | | | | | |
RA Capital Management affiliates(1) | | | | | 60,031,808 | | | | | | 9.3% | | |
New Enterprise Associates affiliates(2) | | | | | 46,447,651 | | | | | | 7.2% | | |
FMR LLC(3) | | | | | 39,219,016 | | | | | | 6.1% | | |
Named Executive Officers, Directors and Director Nominees: | | | | | | | | | | | | | |
David Zaccardelli, Pharm.D.(4) | | | | | 12,667,592 | | | | | | 2.0% | | |
Christina Ackermann | | | | | — | | | | | | * | | |
Michael Austwick | | | | | — | | | | | | * | | |
Ken Cunningham, M.D.(5) | | | | | 426,584 | | | | | | * | | |
Lisa Deschamps(6) | | | | | 430,320 | | | | | | * | | |
David Ebsworth, Ph.D.(7) | | | | | 1,204,643 | | | | | | * | | |
Martin Edwards, M.D.(8) | | | | | 504,800 | | | | | | * | | |
Mahendra Shah, Ph.D.(9) | | | | | 433,080 | | | | | | * | | |
Anders Ullman, M.D., Ph.D.(10) | | | | | 694,856 | | | | | | * | | |
Vikas Sinha(11) | | | | | 554,824 | | | | | | * | | |
James Brady(12) | | | | | 384,000 | | | | | | * | | |
Mark W. Hahn(13) | | | | | 11,756,576 | | | | | | 1.8% | | |
Kathleen Rickard, M.D.(14) | | | | | 2,273,224 | | | | | | * | | |
All directors and executive officers as a group (14 persons)(15) | | | | | 31,330,499 | | | | | | 4.8% | | |
Participants(1) | | | ADSs | | | Non-Voting Ordinary Shares | | ||||||
RA Capital Healthcare Fund L.P. | | | | | 4,596,313 | | | | | | 43,339,542 | | |
Blackwell Partners LLC - Series A | | | | | 503,687 | | | | | | 4,749,354 | | |
AI Biotechnology LLC | | | | | 5,555,556 | | | | | | — | | |
Growth Equity Opportunities 17 LP | | | | | 3,888,889 | | | | | | — | | |
OrbiMed Private Investments VI, LP(2) | | | | | 3,777,778 | | | | | | — | | |
Perceptive Life Sciences Masters Fund, Ltd. | | | | | 2,888,889 | | | | | | — | | |
Abingworth Bioventures VI, LP(3) | | | | | 1,555,556 | | | | | | — | | |
Vivo Venture Fund Cayman VII, L.P.(4) | | | | | 1,244,445 | | | | | | — | | |
Vivo Ventures Fund VII, L.P.(4) | | | | | 304,475 | | | | | | — | | |
Vivo Ventures VII Affiliates Fund, L.P.(4) | | | | | 6,636 | | | | | | — | | |
Novo Holdings A/S(5) | | | | | 1,111,111 | | | | | | — | | |
David Zaccardelli, Pharm.D. | | | | | 55,555 | | | | | | — | | |
Mark W. Hahn | | | | | 22,223 | | | | | | — | | |
Martin Edwards, Ph.D. | | | | | 6,666 | | | | | | — | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| I/We | | | |
| of | | | |
| being a member of the Company, hereby appoint | | | |
| | | | | | Ordinary Resolutions | | | | FOR | | | | AGAINST | | | | WITHHELD | | | | DISCRETION | | | | | | |
| | Resolution 1 | | | | To re-elect | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution 2 | | | | To re-elect | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution 3 | | | | To re-elect Sven Anders Ullman as a director of the Company. | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution 4 | | | | To re-elect | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution | | | | To re-elect | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution 6 | | | | To receive and adopt the U.K. statutory annual accounts and Directors’ report for the year ended 31 December 2023. | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution 7 | | | | To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report for the year ended 31 December 2023. | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution 8 | | | | To receive and approve the U.K. Directors’ Remuneration Policy. | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution 9 | | | | To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration (by way of fee) in accordance with Article 21.4 of the Company’s Articles of Association to £750,000 per annum on an ongoing basis. | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution | | | | To | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution | | | | To | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | Ordinary Resolutions | | | | FOR | | | | AGAINST | | | | WITHHELD | | | | DISCRETION | | | | | | |
| | Resolution 12 | | | | To approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. | | | | | | | | | | | | | | | | | | | | | | |
| | Resolution | | | | |||||||||||||||||||||||
To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of | | | | | | | | | | | | | | | | | | | | | | | ||||||
| | | | | | Special | | | | FOR | | | | AGAINST | | | | WITHHELD | | | | DISCRETION | | | | | | |
| | Resolution | | | | To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if | | | | | | | | | | | | | | | | | | | | | | |